Process optimisation in development of biosimilars

Published: 17.01.2019

Process optimisation for biologics is obligatory for efficient processing and reduction of Cost of Goods (COGs). Especially in the development of biosimilars.

In the current issue of European Biotechnology, Louis Boon (Chief Scientific Officer at Bioceros) describes advantages of using Bioceros’ CHO-BC® platform, easy to transfer to the development laboratories of Polpharma Biologics, in process optimization.

Learn more about metabolic control of this platform using two novel technologies called SPOT™ and SLIM™ as well as how these technologies can help your developments.

DOWNLOAD ARTICLE

written by: Polpharma Biologics

Let’s collaborate and create quality biologics together.

Get in touch for more information.

We use cookies

Polpharma Biologics uses cookies and other similar technologies (hereinafter: cookies) on its webpages and mobile applications (hereinafter, jointly, Website). The user can manage cookies independently by changing the web browser settings. If you do not consent for your personal data to be collected via cookies, you should change your web browser settings or stop using the Website.

Using the Website without changing the web browser settings indicates your acceptance of the use of cookies by Polpharma. Acceptance of the web browser settings indicates your consent to profiling on the basis of the information contained in cookies. Consent may be withdrawn at any time. Withdrawal of consent does not affect lawfulness of any processing activities carried out under consent before its withdrawal.

For more details see the Cookie Policy.